Filing Flows › Comparisons › FATE vs OCGN
Fate Therapeutics vs Ocugen: FATE and OCGN compared
Fate Therapeutics is the larger company: $2.1M of revenue in its latest quarter (Q2 2026) against $2.0M for Ocugen (Q3 2026). Ocugen is growing faster (+11% against +9% a year earlier).
Where the money goes: FATE and OCGN
Fate Therapeutics (FATE) · Q2 2026
Fate Therapeutics, Q2 2026: revenue $2.1M (+9% year over year), net loss $30.2M, operating cash flow −$23.4M. The chart follows the revenue to costs, profit and cash.
Ocugen (OCGN) · Q3 2026
Ocugen, Q3 2026: revenue $2.0M (+11% year over year), operating margin -909.9%, net loss $3.6M, operating cash flow −$15.7M. The chart follows the revenue to costs, profit and cash.
| Fate Therapeutics (FATE) | Ocugen (OCGN) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $2.1M | $2.0M |
| Revenue growth, Y/Y | +9% | +11% |
| Operating margin | n/m | -909.9% |
| Net earnings | −$30.2M | −$3.6M |
| Net margin | — | -184.4% |
| Operating cash flow | −$23.4M | −$15.7M |
Questions
Which is bigger, Fate Therapeutics or Ocugen?
Fate Therapeutics is the larger company: $2.1M of revenue in its latest quarter (Q2 2026) against $2.0M for Ocugen (Q3 2026).
Is Fate Therapeutics or Ocugen growing faster?
Ocugen is growing faster (+11% against +9% a year earlier).
More: Fate Therapeutics earnings · how Fate Therapeutics makes money · Ocugen earnings · how Ocugen makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.